HM-0021005 ER is under clinical development by Hua Medicine Shanghai and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HM-0021005 ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HM-0021005 ER overview
HM-0021005 is under development for the treatment of Type II diabetes mellitus. It is formulated as an extended release tablet administered through oral route.
Hua Medicine Shanghai overview
Hua Medicine Shanghai (Hua) is a Pharmaceutical company. It focuses on developing novel therapies for patients worldwide with unmet medical needs. The company strives to develop therapies for the treatment of diabetes. The company works in collaboration with Covance Pharmaceutical R&D (Beijing) Co., Ltd; Shanghai MedKey Med-Tech Development Co., Ltd; Shanghai and Desano Pharmaceuticals Co., Ltd among others to develop and commercialize its product portfolio. Hua is headquartered in Pudong, shanghai, China.
For a complete picture of HM-0021005 ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
